ITabMed’s aim of “Innovating for Life” continues, with a focus on the discovery and development of cancer immunotherapy treatments. Founded by Yan Xiaoqiang in 2020, ITabMed is backed by 3E Bioventures, Yongjin Group, Regent Capital, and Binhai Capital and is headquartered in Shanghai.